Phone
Email
Altasciences
Business Services · Canada · 1,800 Employees
View Company Info for Free
About
Headquarters
575 Armand-frappier Blvd, Laval, Quebec, H7V 4B...Phone Number
(450) 973-6077Website
www.altasciences.comRevenue
$221.5 MillionIndustry
Who is Altasciences
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexibleapproach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services.Read more
Popular SearchesAltasciences IncAltasciencesAltasciences Preclinical Seattle LLCAltasciences group of companiesVince and Associates Clinical Research IncSIC Code 87,873NAICS Code 54,541Show moreAltasciences Org Chart
PhoneEmailSimilar Companies to Altasciences
563$19.7M1
- 248$35.6M
2
- 170$23.5M
3
- 5,400$9.9B
4
- 252$461.6M
5
- 600$126.8M
6
Altasciences Company Metrics
Acquisitions & Subsidiaries
Jul 18, 2022
Embark Biotech
Jul 18, 2022
Ellab
Jul 18, 2022
Algorithme Pharma
Dec 21, 2021
Clover Life Science
Feb 09, 2020
CalX Instrumentation Services
Mar 20, 2019
Bettera Brands
See More Acquisitions & Subsidiaries
Altasciences Tech Stack
A closer look at the technologies used by Altasciences
Top Companies in Canada
Top 10 companies in Canada by revenue
Top 10 companies in Canada by number of employees
Top 10 companies in Canada by total funding amount
Altasciences News & Media
Altasciences Appoints New General Manager, Clinical Operations
LAVAL, Québec--(BUSINESS WIRE)-- #Altasciences--Altasciences announced the appointment of James Brazeal as General Manager, Clinical Operations, at its clinical facility in Kansas City. James joins Altasciences having previously worked as Vice President of Research at Akron Children’s Hospital, and most recently as Vice President of Research Operations for Circuit Clinical. “James’ proven leadership skills, and deep knowledge of all phases of clinical research, will be invaluable in delivering eJan 29, 2024Altasciences Completes Expansion of New State-Of-The-Art Laboratory in Columbia, Missouri
LAVAL, Québec--(BUSINESS WIRE)-- #Altasciences--Altasciences is pleased to announce the completion of its laboratory facilities in Columbia, MO. The newly expanded, 8,000-square-foot space, which includes a test material department, features state-of-the-art equipment and forty-eight workbenches, with a vast range of services, including ligand binding assays, flow cytometry, biomarker analysis, and cell culture capabilities. “This laboratory expansion is a significant step forward in our abilityOct 31, 2023Angel Reyes Joins Altasciences as General Manager of CDMO Services
LAVAL, Québec--(BUSINESS WIRE)-- #Altasciences--Altasciences is pleased to welcome Angel Reyes as General Manager, Contract Development and Manufacturing Organization (CDMO) Services. Angel joins Altasciences having previously been the Director of Operations at Catalent. He brings to Altasciences over a decade of experience in management and supervisory roles for manufacturing operations and supply chains, having demonstrated an impeccable standard in ensuring adherence to compliance and cGMP poOct 6, 2023Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses
LAVAL, Québec--(BUSINESS WIRE)-- #Altasciences--Altasciences is pleased to have been chosen by Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) (“Virpax”), a company specializing in developing non-addictive products for pain management, PTSD, central nervous system (CNS) disorders, and viral barrier indications, to conduct preclinical studies in support of their development of quaternary ammonium palmitoyl glycol chitosan (GCPQ, under the trade name of AnQlar™). AnQlar is a nanoparticle intended to heSep 21, 2023Altasciences Completes Successful Phase I Trial of Ischemix’ Novel Compound for Treatment of Traumatic Brain Injury (TBI)
LAVAL, Québec--(BUSINESS WIRE)-- #ClinicalTrials--Altasciences is pleased to have completed a Phase I trial on Ischemix, Inc.’s novel, proprietary cytoprotective drug candidate, CMX-2043, for the treatment of acute TBI. The trial was performed at Altasciences’ clinical facility in Montréal. The Phase I trial was performed to evaluate safety, tolerability, and pharmacokinetics in a group of 80 healthy participants in a two-part, double-blind, placebo-controlled study. Single ascending doses (SAD)Aug 30, 2023
Read more news
Frequently Asked Questions regarding Altasciences
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services.... Read More
